A Trial of MBC-11 in Patients With CIBD

Phase 1 Completed 16 enrolled Osteros Biomedica Ltd

NaSingle-groupOpen-labelTreatment

Summary

This study evaluates MBC-11 (a conjugate of a bone-targeting vehicle (etidronate) and a cytostatic agent \[ara-C\] in patients with malignant tumors with CIBD. This is a first use in human.

Timeline

Start: 2014-07
Primary completion: 2015-11
Completion: 2015-12

Publications

Zinnen SP, Karpeisky A, Von Hoff DD, Plekhova L, Alexandrov A. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist. 2019 Mar;24(3):303-e102. doi: 10.1634/theoncologist.2018-0707. Epub 2018 Nov 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MBC-11	Other / unclassified	0.5 mg/kg	Intravenous
Subject	MBC-11	Other / unclassified	1 mg/kg	Intravenous
Subject	MBC-11	Other / unclassified	2.5 mg/kg	Intravenous
Subject	MBC-11	Other / unclassified	5 mg/kg	Intravenous
Subject	MBC-11	Other / unclassified	10 mg/kg	Intravenous
Subject	MBC-11	Other / unclassified	20 mg/kg	Intravenous

A Trial of MBC-11 in Patients With CIBD

Summary

Timeline

Publications

Drugs

Indications